CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus

ML Ong, Matthew Wikstrom, Peter Fleming, Marie Estcourt, PJ Hertzog, GR Hill, Chris Andoniou, Mariapia Degli-Esposti

Research output: Contribution to journalArticle

11 Citations (Scopus)


Major histocompatibility complex class I-restricted T-cell immunity is essential to control infection with cytomegalovirus (CMV), a clinically important virus that causes significant disease in immunocompromised individuals. Cross-presentation is considered the primary mode of antigen presentation to generate protective antiviral CD8+ T-cell immunity. Herpesviruses, including CMV, encode numerous proteins that interfere with direct antigen presentation, leading to the paradigm that T-cell immunity to these pathogens necessitates cross-presentation. However, the antigen presentation requirements needed to generate a protective T-cell response to CMV remain unknown. Here, we show that a fully functional antiviral CD8+ T-cell response can be generated in a system where cross-presentation is shut down by pretreatment with CpG. Notably, in this setting, CD8+ T cells demonstrate accelerated control of infection, and organ pathology is limited. These data indicate that protective antiviral T-cell immunity to CMV is generated by direct presentation and can be enhanced by pretreatment with CpG.
Original languageEnglish
Pages (from-to)55-60
Issue number1
Publication statusPublished - 2013

Fingerprint Dive into the research topics of 'CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus'. Together they form a unique fingerprint.

  • Cite this

    Ong, ML., Wikstrom, M., Fleming, P., Estcourt, M., Hertzog, PJ., Hill, GR., Andoniou, C., & Degli-Esposti, M. (2013). CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus. Blood, 122(1), 55-60. https://doi.org/10.1182/blood-2012-12-471227